drugset / Trial / NCT04454905
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with advanced intrahepatic cholangiocarcinoma (ICC).
Timeline
- Start
- 2020-08-01
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |